 | • レポートコード：MR2211M-4877 • 出版社/出版日：Market Monitor Global / 2022年5月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2-3日） • 産業分類：医薬品 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は次の情報を含め、線維芽細胞増殖因子受容体2阻害剤のグローバル市場規模と予測を記載しています。・線維芽細胞増殖因子受容体2阻害剤のグローバル市場：売上、2017年-2022年、2023年-2028年 ・線維芽細胞増殖因子受容体2阻害剤のグローバル市場：販売量、2017年-2022年、2023年-2028年 ・世界のトップ5企業、2021年 線維芽細胞増殖因子受容体2阻害剤のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000％のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「ASP-5878」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。 線維芽細胞増殖因子受容体2阻害剤のグローバル主要企業は、Advenchen Laboratories、 Amgen、 ArQule、 Santa Cruz Biotechnology、 AstraZeneca、 AVEO Pharmaceuticals、 Batu Biologics、 Boehringer Ingelheim、 Bristol-Myers Squibb Company、 Celon Pharma、 Debiopharm International、 Eddingpharm、 Eisai、 Eli Lilly and Company、 Hutchison MediPharma、 Novartis、 Principia Biopharma、 Vichem Chemie Researchなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル（MMG）社は、線維芽細胞増殖因子受容体2阻害剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の線維芽細胞増殖因子受容体2阻害剤市場：タイプ別、2017年-2022年、2023年-2028年 世界の線維芽細胞増殖因子受容体2阻害剤市場：タイプ別市場シェア、2021年 ・ASP-5878、AZD-4547、BAY-1163877、CPL-043、Debio-1347、EDP-317、その他 世界の線維芽細胞増殖因子受容体2阻害剤市場：用途別、2017年-2022年、2023年-2028年 世界の線維芽細胞増殖因子受容体2阻害剤市場：用途別市場シェア、2021年 ・クリニック、病院、その他 世界の線維芽細胞増殖因子受容体2阻害剤市場：地域・国別、2017年-2022年、2023年-2028年 世界の線維芽細胞増殖因子受容体2阻害剤市場：地域別市場シェア、2021年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における線維芽細胞増殖因子受容体2阻害剤のグローバル売上、2017年-2022年 ・主要企業における線維芽細胞増殖因子受容体2阻害剤のグローバル売上シェア、2021年 ・主要企業における線維芽細胞増殖因子受容体2阻害剤のグローバル販売量、2017年-2022年 ・主要企業における線維芽細胞増殖因子受容体2阻害剤のグローバル販売量シェア、2021年 さらに、当レポートは主要企業のプロファイルを提示します。 Advenchen Laboratories、 Amgen、 ArQule、 Santa Cruz Biotechnology、 AstraZeneca、 AVEO Pharmaceuticals、 Batu Biologics、 Boehringer Ingelheim、 Bristol-Myers Squibb Company、 Celon Pharma、 Debiopharm International、 Eddingpharm、 Eisai、 Eli Lilly and Company、 Hutchison MediPharma、 Novartis、 Principia Biopharma、 Vichem Chemie Research ************************************************************* ・調査・分析レポートの概要 線維芽細胞増殖因子受容体2阻害剤市場の定義 市場セグメント 世界の線維芽細胞増殖因子受容体2阻害剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の線維芽細胞増殖因子受容体2阻害剤市場規模 世界の線維芽細胞増殖因子受容体2阻害剤市場規模：2021年 VS 2028年 世界の線維芽細胞増殖因子受容体2阻害剤市場規模と予測 2017年-2028年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの線維芽細胞増殖因子受容体2阻害剤の売上 グローバルトップ3およびトップ5企業、2021年売上ベース グローバル企業の線維芽細胞増殖因子受容体2阻害剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ASP-5878、AZD-4547、BAY-1163877、CPL-043、Debio-1347、EDP-317、その他 線維芽細胞増殖因子受容体2阻害剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：クリニック、病院、その他 線維芽細胞増殖因子受容体2阻害剤の用途別グローバル売上・予測 ・地域別市場分析 地域別線維芽細胞増殖因子受容体2阻害剤市場規模 2021年と2028年 地域別線維芽細胞増殖因子受容体2阻害剤売上・予測 北米市場 - アメリカの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - カナダの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - メキシコの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 ヨーロッパ市場 - ドイツの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - フランスの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - イギリスの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - イタリアの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - ロシアの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 アジア市場 - 中国の線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - 日本の線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - 韓国の線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - 東南アジアの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - インドの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 南米市場 - ブラジルの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - アルゼンチンの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 中東・アフリカ市場 - トルコの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - イスラエルの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - サウジアラビアの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 - UAEの線維芽細胞増殖因子受容体2阻害剤市場規模2017年-2028年 ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Advenchen Laboratories、 Amgen、 ArQule、 Santa Cruz Biotechnology、 AstraZeneca、 AVEO Pharmaceuticals、 Batu Biologics、 Boehringer Ingelheim、 Bristol-Myers Squibb Company、 Celon Pharma、 Debiopharm International、 Eddingpharm、 Eisai、 Eli Lilly and Company、 Hutchison MediPharma、 Novartis、 Principia Biopharma、 Vichem Chemie Research ... |
Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm.
This report contains market size and forecasts of Fibroblast Growth Factor Receptor 2 Inhibitor in Global, including the following market information:
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Fibroblast Growth Factor Receptor 2 Inhibitor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ASP-5878 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Fibroblast Growth Factor Receptor 2 Inhibitor include Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim and Bristol-Myers Squibb Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Fibroblast Growth Factor Receptor 2 Inhibitor companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Segment Percentages, by Type, 2021 (%)
ASP-5878
AZD-4547
BAY-1163877
CPL-043
Debio-1347
EDP-317
Others
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Segment Percentages, by Application, 2021 (%)
Clinic
Hospital
Others
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Fibroblast Growth Factor Receptor 2 Inhibitor revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Fibroblast Growth Factor Receptor 2 Inhibitor revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Advenchen Laboratories
Amgen
ArQule
Santa Cruz Biotechnology
AstraZeneca
AVEO Pharmaceuticals
Batu Biologics
Boehringer Ingelheim
Bristol-Myers Squibb Company
Celon Pharma
Debiopharm International
Eddingpharm
Eisai
Eli Lilly and Company
Hutchison MediPharma
Novartis
Principia Biopharma
Vichem Chemie Research
1 Introduction to Research & Analysis Reports
1.1 Fibroblast Growth Factor Receptor 2 Inhibitor Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Overall Market Size
2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size: 2021 VS 2028
2.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Fibroblast Growth Factor Receptor 2 Inhibitor Players in Global Market
3.2 Top Global Fibroblast Growth Factor Receptor 2 Inhibitor Companies Ranked by Revenue
3.3 Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue by Companies
3.4 Top 3 and Top 5 Fibroblast Growth Factor Receptor 2 Inhibitor Companies in Global Market, by Revenue in 2021
3.5 Global Companies Fibroblast Growth Factor Receptor 2 Inhibitor Product Type
3.6 Tier 1, Tier 2 and Tier 3 Fibroblast Growth Factor Receptor 2 Inhibitor Players in Global Market
3.6.1 List of Global Tier 1 Fibroblast Growth Factor Receptor 2 Inhibitor Companies
3.6.2 List of Global Tier 2 and Tier 3 Fibroblast Growth Factor Receptor 2 Inhibitor Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type – Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Markets, 2021 & 2028
4.1.2 ASP-5878
4.1.3 AZD-4547
4.1.4 BAY-1163877
4.1.5 CPL-043
4.1.6 Debio-1347
4.1.7 EDP-317
4.1.8 Others
4.2 By Type – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue & Forecasts
4.2.1 By Type – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2022
4.2.2 By Type – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2023-2028
4.2.3 By Type – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2021 & 2028
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue & Forecasts
5.2.1 By Application – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2022
5.2.2 By Application – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2023-2028
5.2.3 By Application – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region – Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2021 & 2028
6.2 By Region – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue & Forecasts
6.2.1 By Region – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2022
6.2.2 By Region – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2023-2028
6.2.3 By Region – Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country – North America Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2028
6.3.2 US Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.3.3 Canada Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.3.4 Mexico Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4 Europe
6.4.1 By Country – Europe Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2028
6.4.2 Germany Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4.3 France Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4.4 U.K. Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4.5 Italy Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4.6 Russia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4.7 Nordic Countries Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.4.8 Benelux Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.5 Asia
6.5.1 By Region – Asia Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2028
6.5.2 China Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.5.3 Japan Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.5.4 South Korea Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.5.5 Southeast Asia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.5.6 India Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.6 South America
6.6.1 By Country – South America Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2028
6.6.2 Brazil Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.6.3 Argentina Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Revenue, 2017-2028
6.7.2 Turkey Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.7.3 Israel Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.7.4 Saudi Arabia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
6.7.5 UAE Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, 2017-2028
7 Players Profiles
7.1 Advenchen Laboratories
7.1.1 Advenchen Laboratories Corporate Summary
7.1.2 Advenchen Laboratories Business Overview
7.1.3 Advenchen Laboratories Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.1.4 Advenchen Laboratories Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.1.5 Advenchen Laboratories Key News
7.2 Amgen
7.2.1 Amgen Corporate Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.2.4 Amgen Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.2.5 Amgen Key News
7.3 ArQule
7.3.1 ArQule Corporate Summary
7.3.2 ArQule Business Overview
7.3.3 ArQule Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.3.4 ArQule Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.3.5 ArQule Key News
7.4 Santa Cruz Biotechnology
7.4.1 Santa Cruz Biotechnology Corporate Summary
7.4.2 Santa Cruz Biotechnology Business Overview
7.4.3 Santa Cruz Biotechnology Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.4.4 Santa Cruz Biotechnology Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.4.5 Santa Cruz Biotechnology Key News
7.5 AstraZeneca
7.5.1 AstraZeneca Corporate Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.5.4 AstraZeneca Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.5.5 AstraZeneca Key News
7.6 AVEO Pharmaceuticals
7.6.1 AVEO Pharmaceuticals Corporate Summary
7.6.2 AVEO Pharmaceuticals Business Overview
7.6.3 AVEO Pharmaceuticals Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.6.4 AVEO Pharmaceuticals Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.6.5 AVEO Pharmaceuticals Key News
7.7 Batu Biologics
7.7.1 Batu Biologics Corporate Summary
7.7.2 Batu Biologics Business Overview
7.7.3 Batu Biologics Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.7.4 Batu Biologics Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.7.5 Batu Biologics Key News
7.8 Boehringer Ingelheim
7.8.1 Boehringer Ingelheim Corporate Summary
7.8.2 Boehringer Ingelheim Business Overview
7.8.3 Boehringer Ingelheim Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.8.4 Boehringer Ingelheim Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.8.5 Boehringer Ingelheim Key News
7.9 Bristol-Myers Squibb Company
7.9.1 Bristol-Myers Squibb Company Corporate Summary
7.9.2 Bristol-Myers Squibb Company Business Overview
7.9.3 Bristol-Myers Squibb Company Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.9.4 Bristol-Myers Squibb Company Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.9.5 Bristol-Myers Squibb Company Key News
7.10 Celon Pharma
7.10.1 Celon Pharma Corporate Summary
7.10.2 Celon Pharma Business Overview
7.10.3 Celon Pharma Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.10.4 Celon Pharma Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.10.5 Celon Pharma Key News
7.11 Debiopharm International
7.11.1 Debiopharm International Corporate Summary
7.11.2 Debiopharm International Business Overview
7.11.3 Debiopharm International Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.11.4 Debiopharm International Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.11.5 Debiopharm International Key News
7.12 Eddingpharm
7.12.1 Eddingpharm Corporate Summary
7.12.2 Eddingpharm Business Overview
7.12.3 Eddingpharm Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.12.4 Eddingpharm Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.12.5 Eddingpharm Key News
7.13 Eisai
7.13.1 Eisai Corporate Summary
7.13.2 Eisai Business Overview
7.13.3 Eisai Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.13.4 Eisai Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.13.5 Eisai Key News
7.14 Eli Lilly and Company
7.14.1 Eli Lilly and Company Corporate Summary
7.14.2 Eli Lilly and Company Business Overview
7.14.3 Eli Lilly and Company Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.14.4 Eli Lilly and Company Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.14.5 Eli Lilly and Company Key News
7.15 Hutchison MediPharma
7.15.1 Hutchison MediPharma Corporate Summary
7.15.2 Hutchison MediPharma Business Overview
7.15.3 Hutchison MediPharma Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.15.4 Hutchison MediPharma Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.15.5 Hutchison MediPharma Key News
7.16 Novartis
7.16.1 Novartis Corporate Summary
7.16.2 Novartis Business Overview
7.16.3 Novartis Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.16.4 Novartis Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.16.5 Novartis Key News
7.17 Principia Biopharma
7.17.1 Principia Biopharma Corporate Summary
7.17.2 Principia Biopharma Business Overview
7.17.3 Principia Biopharma Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.17.4 Principia Biopharma Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.17.5 Principia Biopharma Key News
7.18 Vichem Chemie Research
7.18.1 Vichem Chemie Research Corporate Summary
7.18.2 Vichem Chemie Research Business Overview
7.18.3 Vichem Chemie Research Fibroblast Growth Factor Receptor 2 Inhibitor Major Product Offerings
7.18.4 Vichem Chemie Research Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in Global Market (2017-2022)
7.18.5 Vichem Chemie Research Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer